Detection of Bone Metastases in @entity0 ( XXXX ) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum @entity623 ( @entity623 ), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.

@entity1 @entity0 @entity5 @entity3 @entity204 @entity623
Bone metastases are a serious problem in @entity1 with @entity5 and their presence usually signifies serious morbidity prior to the @entity1 's @entity204 . In @entity0 @entity1 the incidence of bone @entity3 is observed to be very high at 70  %, as seen during post-mortem examination. Bone @entity3 is difficult to diagnose, treat or follow clinically without radiological tools. This study was designed to evaluate the utility of a novel bone resorption marker-serum tartrate-resistant acid phosphatase 5b (TRACP5b) and the bone formation marker such as serum total @entity623 ( @entity623 ), in comparison with whole body skeletal scintigraphy with Technetium99m MDP for the diagnosis of bone metastases (BM) in @entity0 ( @entity0 ) @entity1 . This study is intended to help the clinician to diagnose bone @entity3 without resorting to radiological tools, as they are not cost effective and carry the risk of radiation. EXPERIMENTAL DESIGN: Four groups of samples were analysed. 1st group consists 52 normal female ( @entity5 free @entity1 ), 2nd group consists 38 @entity0 @entity1 without bone @entity3 , 3rd group consists 27 @entity0 @entity1 with limited bone @entity3 (3 or less than 3 skeletal lesions) and 4th group consists 35 @entity0 @entity1 with extensive bone @entity3 (4 or more than 4 skeletal lesions), conformed by whole body skeletal scintigraphy with Technetium99m MDP. One way ANOVA was used to compare serum TRACP5b and serum @entity623 among these groups. Both serum TRACP5b and serum @entity623 are not markedly elevated in limited bone @entity3 but are strongly elevated in extensive bone @entity3 (p  <  0.0001). As seen in this study the biochemical bone resorption marker, serum TRACP5b, abnormally increased in extensive bone @entity3 of @entity0 @entity1 and can be used as a specific marker for bone @entity3 in lieu of radiological tools.
